Abstract
Introduction

Hyponatremia is defined by a serum sodium concentration of less than 136 mmol/L (1). It is the most frequent electrolyte disorder of patients in the hospital (2) but it is also encountered in ambulatory outpatients especially in the elderly
. The incidence of hyponatremia has apparently increased over the last 3 decades. Although a prospective study from 1985 reported an incidence of 2.5% from a tertiary care medical center (4) , more recent studies from 2003 (5) and 2006 (2) found this number to be between 29 and 42%. Although hyponatremia in the hospital was not limited to special fields of medical practice, the departments of internal medicine, surgery and gynaecology and the areas of intensive care, pulmonology and cardiology were those most heavily involved (2) .
Clincal Relevance of Hyponatremia
Until recently the clinical relevance of hyponatremia, especially in its mild form (130-134 mmol/L) was not clarified. Clinicians saw hyponatremia primarily as an important diagnostic marker which indicated the presence of heart failure, liver cirrhosis or neoplastic disease. Clinicians were also well aware that acute severe hyponatremia (a serum sodium concentration <118 mmol/L of a duration <36-48 hours) would lead to serious symptoms such as confusion, unconsciousness, grand mal seizures and even death. Hence, it was common to direct therapy at the prevention of progression from mild to severe hyponatremia. However mild hyponatremia in itself which is by far the commonest form of hyponatremia encountered was considered oligosymptomatic, exerting little if any impairment of the patient's wellbeing. There have been several recent changes regarding the viewpoint of these aspects.
There is new evidence that even mild hyponatremia is a cause of important symptoms (3) . Renneboog et al (3) evaluated mental functions in 16 (6) . In this cohort of obviously very sick patients hyponatremia turned out to be an independent predictor of survival or premature demise even when the score of severity the MELD score was average and not extreme (6) . In a similar line, hyponatremia at the time of liver transplantation was associated with a larger intensity of neurologic disease, renal failure, infectious complications and early posttransplantation demise than normonatremia (7) . These recent publications therefore reinforce previous knowledge depicting hyponatremia as a marker of a guarded prognosis; yet they leave the second question unanswered: does it actively contribute to an adverse prognosis?
In chronic cardiac disease hyponatremia is frequently seen. As has been well described several years ago hyponatremia in that setting predicts worsening of the heart failure and an unfavourable prognosis (8) . It has now been shown that hyponatremia is also a common finding in acute STelevation myocardial infarction (9) . A recent study of 978 acute ST-elevation myocardial infarction patients showed that hyponatremia predicted post discharge re-hospitalization and post discharge demise (9) (10) . (29) . However the peptidic nature of the agents, the need for (Fig. 1) .
Pathophysiology of Hyponatremia
Vasopressin Antagonists
The pathogenetic role of ADH in most types of hyponatremia suggested that vasopressin antagonists would be a suitable approach to treatment. Manning et al were the first to describe a large number of peptidic vasopressin antagonists (28). It was shown that antagonists worked in principle in animal models with hyponatremia and in human subjects
F i g u r e 1 . Ch e mi c a l s t r u c t u r e o f n o n p e p t i d e , o r a l l y a v a i la b l e v a s o p r e s s i n a n t a g o n i s t s . Al l c o mp o u n d s a r e v a s o p r e s s i n V-2 r e c e p t o r a n t a g o n i s t s e x c e p t f o r c o n i v a p t a n wh i c h i s a mi x e d V-1 / V-2 v a s o p r e s s i n r e c e p t o r a n t a g o n i s t . ( Co n i v a p t a n i s p r e s e n t l y o n t h e ma r k e t a s a p a r e n t e r a l p r e p a r a t i o n ) parenteral application and the unexpected property of intrinsic agonistic effects in addition to antagonistic effects precluded any widespread or chronic use in patients. It was therefore a breakthrough that random screening between 1990 and 2000 yielded several non-peptide, orally available novel vasopressin antagonists collectively called vaptans
Mozavaptan
OPC 31260 or mozavaptan was described in 1992 (30) . It is a benzazepine derivative (Fig. 1) 
that bound with a high degree of affinity to the renal hydroosmotic V-2 vasopressin receptor but not to the vascular V-1 vasopressin receptor. It did not cause agonistic effects of its own. When given orally to normal human subjects at a dose of 1 mg/kg the urinary flow rate increased eight fold, the urinary osmolality became maximally dilute (63 mosm/kg) but the urinary sodium excretion rate changed only marginally (31). Although mozavaptan was the first agent of the new class of vaptans and hence had paradigmatic importance mozavaptan was not very potent. Mozavaptan eventually met with limited clinical application and subsequent agents have attracted greater interest.
Lixivaptan
VPA 985 or lixivaptan is a potent, V-2 receptor selective, orally available vasopressin antagonist reported in 1998 (32).
Recently, a short term study in 42 heart failure patients receiving lixivaptan was reported (33) . When lixivaptan was given in doses as high as 400 mg the urinary excretion rate more than doubled, solute-free water excretion was significantly enhanced and the serum sodium concentration increased (33 
Conivaptan
Conivaptan or YM 087 is the first combined V-1a/V-2 vasopressin receptor antagonist (35). A few clinical studies have been reported using conivaptan as a parenteral preparation (36). [Although originally developed as an oral antagonist it was later marketed as a parenteral agent only]. The studies included patients with SIADH and hyponatremic cardiac failure. Conivaptan was given as a continuous i.v. infusion over 9 days in doses of
Satavaptan
Satavaptan or SR 121 463 is a potent, specific orally available vasopressin V-2 receptor antagonist first described in 1996 (37) . Clinical phase III studies have been conducted in SIADH (38) . Thirty-four hyponatremic patient received 25 or 50 mg orally once a day of satavaptan for 5 to 23 days, or placebo in a double-blind, randomized fashion (38) . Patients maintained a fluid restriction of 1.5 L/day. In this study satavaptan increased the urinary flow rate from 1.5 to 2.5 L/day over the first 5 days of the protocol. The urinary osmolality decreased by more than 50%, the free-water clearance became positive and the hyponatremia corrected from 127 ± 5 mmol/L to 140 ± 6 (38) . In the treated patients there were no significant changes of the urinary excretion rats of sodium or potassium. Despite the increased urine flow patients failed to lose weight. While this lack of a weight loss has been seen in several long term clinical studies of vaptans in the satavaptan study (38) (43) (Fig. 2) 
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